Dynavax Technologies (NASDAQ:DVAX) Stock Rating Reaffirmed by HC Wainwright

HC Wainwright reiterated their buy rating on shares of Dynavax Technologies (NASDAQ:DVAX) in a report issued on Wednesday morning, Benzinga reports. The brokerage currently has a $29.00 price target on the biopharmaceutical company’s stock. HC Wainwright also issued estimates for Dynavax Technologies’ Q4 2024 earnings at $0.02 EPS, FY2024 earnings at $0.17 EPS, FY2025 earnings at $0.20 EPS and FY2026 earnings at $0.33 EPS.

Separately, StockNews.com cut Dynavax Technologies from a buy rating to a hold rating in a research note on Tuesday, May 28th. Two research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to data from MarketBeat, Dynavax Technologies presently has a consensus rating of Moderate Buy and a consensus price target of $23.67.

Dynavax Technologies Trading Up 3.7 %

Shares of DVAX stock traded up $0.40 on Wednesday, hitting $11.10. The company had a trading volume of 2,976,587 shares, compared to its average volume of 2,151,702. The firm has a market cap of $1.45 billion, a P/E ratio of 185.00 and a beta of 1.28. The stock’s 50-day moving average is $11.20 and its two-hundred day moving average is $11.84. The company has a debt-to-equity ratio of 0.36, a quick ratio of 14.10 and a current ratio of 15.20. Dynavax Technologies has a twelve month low of $9.74 and a twelve month high of $15.15.

Dynavax Technologies (NASDAQ:DVAX) last issued its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical company reported $0.08 earnings per share for the quarter, beating the consensus estimate of $0.06 by $0.02. Dynavax Technologies had a return on equity of 1.52% and a net margin of 3.91%. The company had revenue of $73.80 million during the quarter, compared to analysts’ expectations of $76.92 million. During the same quarter in the prior year, the firm posted $0.03 earnings per share. On average, equities research analysts anticipate that Dynavax Technologies will post 0.12 earnings per share for the current fiscal year.

Insider Activity

In related news, Director Francis Cano sold 3,615 shares of Dynavax Technologies stock in a transaction on Friday, May 31st. The stock was sold at an average price of $11.93, for a total transaction of $43,126.95. Following the sale, the director now directly owns 36,905 shares in the company, valued at $440,276.65. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 2.98% of the company’s stock.

Institutional Trading of Dynavax Technologies

Hedge funds have recently bought and sold shares of the business. Nordea Investment Management AB lifted its holdings in Dynavax Technologies by 23.0% during the first quarter. Nordea Investment Management AB now owns 393,781 shares of the biopharmaceutical company’s stock worth $4,924,000 after acquiring an additional 73,681 shares during the period. Mizuho Markets Americas LLC lifted its holdings in Dynavax Technologies by 16.9% during the first quarter. Mizuho Markets Americas LLC now owns 852,057 shares of the biopharmaceutical company’s stock worth $10,574,000 after acquiring an additional 123,300 shares during the period. Dimensional Fund Advisors LP lifted its holdings in Dynavax Technologies by 7.8% during the fourth quarter. Dimensional Fund Advisors LP now owns 4,032,139 shares of the biopharmaceutical company’s stock worth $56,372,000 after acquiring an additional 293,337 shares during the period. Parkman Healthcare Partners LLC bought a new stake in Dynavax Technologies during the fourth quarter worth $3,550,000. Finally, Rafferty Asset Management LLC increased its position in Dynavax Technologies by 13.4% in the fourth quarter. Rafferty Asset Management LLC now owns 540,319 shares of the biopharmaceutical company’s stock worth $7,554,000 after buying an additional 63,685 shares during the last quarter. 96.96% of the stock is currently owned by institutional investors.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.